Peri-Implantitis and Peri-implant Mucositis Clinical Trial
Official title:
The Use of Erythritol Powder and Locally Derived Metronidazole for the Non-surgical Treatment of Peri-implant Mucositis and Peri-implantitis.
20 consecutive adult implant patients, presenting the signs of peri-implant mucositis
(probing depth ≥4 mm combined with bleeding and/or pus on probing) or initial
peri-implantitis (probing depth ≥4 mm, bleeding and suppuration plus radiographic loss of
supporting bone ≤30% compared with the situation after implant placement) will be included.
Sites will be treated by ultrasonic debridement of the pocket, performed using a
piezoceramic ultrasonic device. For the purpose, a Tip will be connected to the Handpiece
Led (5 minutes/pocket) . Then, it will be followed by the subgingival use of erythritol
powder applied by the use of Handpiece connected to an airflow unit 2x5 seconds/pocket. At
this time the subgingival delivery of metronidazole gel will be provided. After
instrumentation, patients will rinse with chlorhexidine 0.20% 3 times/day for 2 weeks.
At baseline, 1 month, 3 months and 6 months the following parameters will be evaluated:
Probing Pocket depth (PPD), Bleeding on Probing (BoP), Clinical Attachment Level (CAL).
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05897736 -
Salivary Minerals in Patients With Peri-implantitis
|